Oncolys BioPharma Inc. (TYO:4588)

Market Cap	92.21B +550.7%
Revenue (ttm)	28.55M -9.0%
Net Income	-2.06B
EPS	-82.55
Shares Out	29.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,616,800
Average Volume	2,117,815
Open	2,930.00
Previous Close	2,937.00
Day's Range	2,895.00 - 3,175.00
52-Week Range	458.00 - 3,160.00
Beta	0.91
RSI	71.25
Earnings Date	Feb 6, 2026

About Oncolys BioPharma

Oncolys BioPharma Inc. engages in the research, development, manufacturing, and sale of viral infectious disease treatment drugs in Japan, the United States, and Asia. The company offers Telomelysin (OBP-301), an oncolytic adenovirus, which is in Phase II clinical trial for the treatment of esophageal, gastric, and head and neck cancers, as well as hepatocellular carcinoma; and OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor, which is in Phase IIb clinical trial for the treatment of HIV infection. It also provides products i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 42
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4588

Financial Performance

In 2024, Oncolys BioPharma's revenue was 31.38 million, a decrease of -50.21% compared to the previous year's 63.04 million. Losses were -1.68 billion, -13.09% less than in 2023.